20324 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
#2Edaravone Oral Solution Compositions
#3l,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES
#4METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
#5ACSS2 INHIBITORS AND METHODS OF USE THEREOF
#6METHOD OF TREATING DISEASE
#7STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE
#8Pharmaceutical Formulation and Dosing Regimen for the Treatment of Amyotrophic Lateral Sclerosis
#9PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
#10COMBINATION THERAPY OF TRADITIONAL CHINESE AND MODERN MEDICINE FOR TREATMENT OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
#11TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT
#12PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF
#13TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT
#14SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER
#15STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE
#16PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
#17STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE
#18EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION
#19ACSS2 INHIBITORS AND METHODS OF USE THEREOF
#20COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND RELATED DISORDERS
#21METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
#22COMPOSITION AND METHOD FOR EVALUATING RESPONSIVENESS OF EDARAVONE
#23MEDICAL AGENT FOR TREATING OR SUPPRESSING PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
#24METHODS FOR INHIBITING PARASITIC GLUCOKINASE AND/OR HEXOKINASE
#25PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
#26Pharmaceutical composition for oral administration of edaravone and method of administering same
#27USE OF EDARAVONE IN TREATMENT OF AUTISM SPECTRUM DISORDER
#28METHODS FOR DEFINING STAGES AND PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
#29COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY
#30PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID
#31(S)-5-(1-(3,5-BIS(TRIFLUOROMETHYL)PHENOXY)ETHYL)CYCLOHEXANE-1,3-DIONE (NU-9) IMPROVES THE HEALTH OF DISEASED UPPER MOTOR NEURONS
#32SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS
#33DRIVING AXON REGENERATION BY NRF2 OVEREXPRESSION AND EDARAVONE APPLICATION
#34PHARMACEUTICAL AND FOOD COMPOSITIONS FOR THE PREVENTION, ALLEVIATION, OR TREATMENT OF INFLAMMATORY DISEASES COMPRISING 1-ALKYL-5-ARYLIDENE-2-SELENOXOIMIDAZOLIDIN-4-ONE AND ITS DERIVATIVES
#35Covalent Inhibitors As Antiviral Agents
#36COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER
#37STABLE PHARMACEUTICAL COMPOSITIONS OF EDARAVONE
#38FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER
#39PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES
#40COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS
#41COMPOSITIONS AND METHODS FOR TREATING NEUROMUSCULAR DISORDERS
#42Methods of Treating Retinal Vasculopathies
#43EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION
#44MEDICAMENT
#45PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME
#46COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF
#47TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT
#48USE OF COMPOSITION CONTAINING CILOSTAZOL IN CEREBROVASCULAR DISEASES
#49METHODS, ASSAYS AND COMPOSITIONS FOR MEASURING BRAIN DAMAGE OR HARM DURING SURGERY
#50Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
#51METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS AND METHOD FOR SUPPRESSING PROGRESS OF AMYOTROPHIC LATERAL SCLEROSIS
#52COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH
#53Edaravone suspension for oral administration
#54USE OF COMPOSITION IN TREATMENT OF CEREBRAL STROKE
#55NK CELLS OR T CELLS EXPRESSING CHIMERIC HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE
#56CONJOINT THERAPIES FOR TREATING VIRAL INFECTIONS
#57Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient
#58STABLE PHARMACEUTICAL COMPOSITION
#59Pharmaceutical composition for oral administration of edaravone and method of administering same
#60INHIBITION OF BAX-MEDIATED CELL DEATH BY ELTROMBOPAG
#61USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS
#62Method for treating hypertension by using compound
#63Pemafibrate dosing regimens
#64ACSS2 INHIBITORS AND METHODS OF USE THEREOF
#65Edaravone suspension for oral administration
#66PHARMACEUTICAL COMPOSITION COMPRISING ELTROMBOPAG BIS(MONOETHANOLAMINE)
#67Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
#68PHARMACEUTICAL COMPOSITION COMPRISING ELTROMBOPAG BIS(MONOETHANOLAMINE)
#69ORAL FORMULATIONS OF EDARAVONE AND METHOD OF MANUFACTURING THEREOF
#70METHOD OF TREATING DISEASE
#71METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS
#72ELTROMBOPAG DOSING REGIMEN
#73ACSS2 inhibitors and methods of use thereof
#74Pemafibrate dosing regimens
#75Compositions and methods for the treatment of amyotrophic lateral sclerosis, parkinson's disease, parkinson's disease with dementia, dementia with lewy bodies, and multiple system atrophy
#76Pemafibrate dosing regimens
#77Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient
#78Synergistic combination therapy for treating ALS
#79CELL-FREE MIRNA BIOMARKERS FOR PROGNOSIS AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES
#80Methods and compositions for neuroprotection
#81COMBINED THERAPY FOR NMDAR ANTAGONIST-RESPONSIVE NEUROPSYCHIATRIC DISORDERS
#82Pharmaceutical composition for oral administration of edaravone and method of administering same
#83Edaravone suspension for oral administration
#84STABLE PARENTERAL DOSAGE FORM OF PYRAZOLONE DERIVATIVE
#85ANALYSIS METHOD OF 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT, TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS, INHIBITION OF PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS, AND METHOD OF PRODUCING MEDICAMENT CONTAINING 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE ACTIVE PHARMACEUTICAL INGREDIENT
#86B CELL IMMUNOTHERAPY
#87ELTROMBOPAG CHOLINE DOSAGE FORMS
#88Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
#89PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF
#90Pharmaceutical composition and use thereof
#91Composition for preventing or treating SARS coronavirus 2 infection disease
#92LIQUID DOSAGE FORM OF EDARAVONE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF WHICH IS STABLE IN STORAGE, TRANSPORTATION AND USE
#93PHARMACEUTICAL COMPOSITION COMPRISING ELTROMBOPAG OLAMINE
#94METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
#95Edaravone suspension for oral administration
#96Edaravone pharmaceutical composition
#97METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
#98COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING FILARIAL DISEASE
#99Edaravone suspension for oral administration
#100Chimeric Growth Factor Receptors
#101USE OF GABOXADOL IN THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND ASTHMA
#1023'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
#103METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS AND METHOD FOR SUPPRESSING PROGRESS OF AMYOTROPHIC LATERAL SCLEROSIS
#104Formulations for treatment of post-traumatic stress disorder
#105DRUG CONTAINING PYRAZOLONE DERIVATIVE
#106Method of inhibiting growth using eltrombopag
#107Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
#108Injectable pharmaceutical formulation
#109Methods and compositions associated with the granulocyte colony-stimulating factor receptor
#110Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy
#111ANALYSIS METHOD OF 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE BULK DRUG, TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS, INHIBITION OF PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS, AND METHOD OF PRODUCING DRUG CONTAINING 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE BULK DRUG
#112Transdermal penetrant formulations containing cannabidiol
#113Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
#114Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
#115Compositions and Methods for Treatment and Prevention of Pyrexia in Horses
#116Sublingual pharmaceutical compositions of edaravone and (+)-2-borneol
#117CANCER TREATMENT METHOD
#118Edaravone suspension for oral administration
#119Methods for treating amyotrophic lateral sclerosis
#120Combination of a PI3K-inhibitor with an androgen receptor antagonist
#121METHODS AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS
#122Method of treating amyotrophic lateral sclerosis with pridopidine
#123Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
#124USE OF EDARAVONE IN ORAL TREATMENT OF OXIDATIVE-STRESS MEDIATED NEURODEGENERATIVE DISORDERS
#125MEDICAMENT
#126Methods for treating amyotrophic lateral sclerosis
#127TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS
#128PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFLAMMATORY EAR DISEASES, METHOD FOR PRODUCING SAME AND METHOD FOR TREATMENT USING SAME COMPOSITION
#129Methods of Using Metamizole for Treatment of Pyrexia in Equines
#130MEDICINAL COMPOSITION INHIBITING NEOVASCULARIZATION PROLIFERATION FACTOR
#131TREATMENT COMPRISING ORAL OR GASTRIC ADMINISTRATION OF EDARAVONE
#132Medical treatment comprising enteral administration of edaravone
#133Dose and regimen for HDM2-p53 interaction inhibitors
#134CANCER TREATMENT METHOD
#135ACSS2 inhibitors and methods of use thereof
#1363'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE)
#137Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
#138FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA
#139Edaravone dosage form
#140FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA
#141METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
#142THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF
#1431-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF
#144CANCER TREATMENT METHOD
#145Methods and compositions associated with the granulocyte colony-stimulating factor receptor
#146Method of treating disease
#147Formulations for treatment of post-traumatic stress disorder
#1483'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE)
#149TARGETING OF THE FORMYL-PEPTIDE RECEPTOR 2/LIPOXIN A4 RECEPTOR (FPR2/ALX) FOR TREATMENT OF HEART DISEASE
#150Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis
#151Compositions favoring wound repair
#152Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect
#153THERAPEUTIC PUTTY HAVING ANALGESICS AND/OR COUNTERIRRITANTS
#154PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS
#155Method for producing mesenchymal cells with promoted c-MPL receptor expression on cell surface
#156PLASTIC CONTAINER COMPRISING CYCLIC POLYOLEFIN LAYER
#157N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors and uses thereof
#158Methods of treatment associated with the granulocyte colony-stimulating factor receptor
#1593'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE)
#160Compositions and methods for treatment and prevention of pyrexia in horses
#161Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
#162PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFLAMMATORY EAR DISEASES, METHOD FOR PRODUCING SAME AND METHOD FOR TREATMENT USING SAID COMPOSITION
#163SIGMA LIGANDS FOR POTENTIATING THE ANALGESIC EFFECT OF OPIOIDS AND OPIATES IN POST-OPERATIVE PAIN AND ATTENUATING THE DEPENDENCY THEREOF
#164METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
#165Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors
#166Pyrazolone compounds having human neutrophil elastase inhibitory properties
#167METHODS OF PREVENTING AND TREATING CEREBRAL AMYLOID ANGIOPATHY (CAA) WITH AN EDARAVONE MEDICAMENT
#168INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GOUT AND PREPARATION METHOD THEREOF
#169Dyslipidemia therapeutic agent
#170Perk activator for the treatment of neurodegenerative diseases
#1713'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE)
#172CANCER TREATMENT METHOD
#173Agent for preventing and/or treating ophthalmologic diseases
#174MEDICINAL COMPOSITION INHIBITING NEOVASCULARIZATION PROLIFERATION FACTOR
#1753'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE)
#176Methods and compositions for treating infection
#177MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
#178Antifungal composition
#179Methods and compositions associated with the granulocyte colony-stimulating factor receptor
#180METHODS AND COMPOSITIONS FOR TREATING CANCER
#181Pharmaceutical Combination
#182TOPICAL COMPOSITIONS COMPRISING MODULATORS OF TRPM8
#183STABLE ORAL PHARMACEUTICAL COMPOSITION
#184Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity
#185METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
#186Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
#187CANCER TREATMENT METHOD
#1883'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE)
#189COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS
#190Compositions of eltrombopag
#191THROMBOPOIETIN RECEPTOR LIGANDS FOR NEUROPROTECTION
#192METHODS OF TREATING DEGENERATIVE DISEASES/INJURIES
#193Method of treating disease by auricular anesthesia of cranial nerves
#194Pharmaceutical Combination
#195Methods of treatment associated with the granulocyte colony-stimulating factor receptor
#196Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
#197COMBINATION
#198Controlled HNO release through intramolecular cyclization-elimination
#199INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GOUT AND PREPARATION METHOD THEREOF
#200Inhalation-type pharmaceutical composition for the treatment of arthritis and preparation method thereof
#201Inhalation-type pharmaceutical composition for the treatment of heart disease and preparation method thereof
#202Inhalation-type pharmaceutical composition for the treatment of Alzheimer's disease and preparation method thereof
#203Inhalation-type pharmaceutical composition for the treatment of Parkinson's disease and preparation method thereof
#204CYCLIC AMIDE DERIVATIVE
#205Method of treating and preventing brain impairment using Na-K-2Cl-cotransporter isoform 1 inhibitors
#206SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE
#207METHODS OF TREATMENT, DIAGNOSIS AND MONITORING FOR METHAMPHETAMINE TOXICITY WHICH TARGET CERAMIDE METABOLIC PATHWAYS AND CELLULAR SENESCENCE
#208Pharmaceutical Composition for Headache Relief
#209Method of modulating ribonucleotide reductase
#2103'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID bis-(MONOETHANOLAMINE)
#211Positive allosteric modulators for melanocortin receptors
#2121-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
#213Treatment of inflammatory disorders in non-human mammals
#214Lupane triterpenoid derivatives and pharmaceutical use thereof
#215Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
#216Pyrazolone derivatives as PDE4 inhibitors
#2173,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
#218METHOD OF TREATING DISEASE BY AURICULAR ANESTHESIA OF CRANIAL NERVES
#219COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS
#220Formulations and Methods for Treating Ear Conditions
#2213'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#222Methods and compositions associated with the granulocyte colony-stimulating factor receptor
#223Methods for Treating Degenerative Diseases/Injuries
#224CANCER TREATMENT METHOD
#225THROMBOPOIETIN MIMETICS FOR THE TREATMENT OF RADIATION OR CHEMICAL INDUCED BONE MARROW INJURY
#226Isometheptene isomer
#227Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
#228METHODS AND COMPOUNDS TO INHIBIT ENVELOPED VIRUS RELEASE
#229METHOD OF SELECTING THERAPEUTIC INDICATIONS
#230METHOD OF TREATING THROMBOCYTOPENIA
#231Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
#232METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
#233Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay
#234PHARMACEUTICAL COMPOSITION COMPRISING TPO OR AN AGONIST OF THE TPO RECEPTOR
#235THROMBOPOIETIN MIMETICS FOR THE TREATMENT OF RADIATION OR CHEMICAL INDUCED BONE MARROW INJURY
#236CANCER TREATMENT METHOD
#2373′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#238TOPICAL COMPOSITIONS
#239Non peptidic 14-3-3 inhibitors and the use thereof
#240Pharmaceutical Combination
#241COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS
#242Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
#243Methods for Treating Degenerative Diseases/Injuries
#244Methods and systems for identifying and treating anti-progestin sensitive tumors
#245Pyrazolone derivatives as PDE4 inhibitors
#2464-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
#247INTERFERON-INDUCING COMPOUNDS AND USES THEREOF
#248CANCER TREATMENT METHOD
#249Non-peptide thrombopoietin receptor agonist in the treatment of cancer and pre-cancerous syndromes
#250Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
#251Pharmaceutical compositions comprising sigma receptor ligands
#252PLASTIC CONTAINER COMPRISING CYCLIC POLYOLEFIN LAYER
#2533,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
#2543'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID bis-(MONOETHANOLAMINE)
#255Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets
#256Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
#257METHOD OF TREATING THROMBOCYTOPENIA
#258Methods of modulating uric acid levels
#259USE OF IL-1 ANTAGONISTS TO TREAT PSEUDOGOUT
#260Inhibitors of bacterial type III secretion system
#2613′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#262Detection and treatment of schizophrenia
#263Methods of administration of thrombopoietin agonist compounds
#264MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
#2654-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
#266Method for treating a B-raf associated cancer with an Hsp90 inhibitor
#267METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
#268Compositions and methods for treating amyloidosis
#269COMPOSITIONS AND METHODS FOR INHIBITING EZH2
#270Method for the preventing and/or treating IL-1 beta lung pathology in mammals by administering a uric acid reducing compound
#271Topical Composition
#272Method for identifying compounds useful for treating and/or preventing disease-associated bone loss
#273METHODS OF TREATING DEGENERATIVE DISEASES/INJURIES
#274Pyrazole compounds and uses thereof
#275CANCER TREATMENT METHOD
#276CANCER TREATMENT METHOD
#2772-methyl-5-imino-benzo[D][1 ,3]oxazin[5-B]pyrazole compound, preparation and use thereof
#278ANTI-INFLAMMATORY DRUG DELIVERY SYSTEM
#279Treatment of Inflammatory Conditions
#2801-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
#2813′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#282Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
#283Plastic container comprising cyclic polyolefin layer
#284Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
#285METHOD FOR TREATING INFECTIONS
#286SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE
#287Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
#288Detection and treatment of schizophrenia
#289Use of IL-1 antagonists to treat gout
#290Pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases
#2913,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
#292PLASTIC CONTAINER COMPRISING CYCLIC POLYOLEFIN LAYER
#293Therapeutic compounds
#294Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
#295COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING
#296OIL-BASED NSAID COMPOSITIONS AND METHODS FOR MAKING AND USING SAME
#297Pyrazolone derivative formulations
#298NOVEL PHARMACEUTICAL COMPOSITION
#299Pyrazolone derivatives as PDE4 inhibitors
#300SYNTHESIS OF NOVEL TUBULIN POLYMERIZATION INHIBITORS: BENZOYLPHENYLUREA (BPU) SULFUR ANALOGS